Matthew Zirwas, MD

Zirwas spoke with Dermatology Times to share the top clinical pearls and key takeaways from his discussion on contact dermatitis.

Zirwas presented 2 sessions at SDPA on innovative care strategies for patients with AD and other itch-related diseases.

Click here to test your knowledge and read more about the treatment landscape of chronic hand eczema.

During an interview with Dermatology Times, Zirwas outlined modern allergens such as sulfites, dietary nickel, and acrylates.

From dupilumab to OX40s, Zirwas talked about the niche to all atopic dermatitis therapies to make the best decision with your patient.

In a session at Maui Derm NP+PA Fall, Zirwas talked about the newfound discoveries of causation within the AD space.

Matthew Zirwas, MD, hosted a Case-Based Roundtable discussion to review 2 challenging cases of atopic dermatitis involving intense itch and severe hand dermatitis.

Linda Stein Gold, MD, and Matthew Zirwas, MD, share some advice for clinicians on how to discuss JAK inhibitors with patients.

Dr Matthew Zirwas describes his experience using JAK inhibitor ruxolitinib in his clinical practice.

Clinicians provide insight into the risk of high systemic absorption levels with JAK inhibitor treatments.

Matthew Zirwas, MD, breaks down the safety of JAK inhibitors based on clinical trial data.

Key opinion leaders explain the box warnings and safety profiles of JAK inhibitors.

Linda Stein Gold, MD, provides an overview of the four JAK inhibitors currently available for treating inflammatory diseases.